12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CVT-301: Phase I data

Top-line data from a dose-ranging Phase I trial in healthy volunteers showed that CVT-301 was safe and well tolerated. Additionally, CVT-301 was immediately absorbed with dose-proportional pharmacokinetics,...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >